DHX Company and Ezenome Highlight Third-Generation Microbiome-Based Pet Healthcare

DHX Company announced on February 3 that it will launch a joint venture in the companion animal healthcare sector with Ezenome, a company specializing in microbiome analysis, to provide precision health management services based on microbiome technology.

The ICT Distribution Division of DHX Company plans to lead this initiative by selling a pet microbiome diagnostic kit for dogs, which achieves 99.9% accuracy using third-generation microbiome analysis technology, through its Orclover online mall. The company holds exclusive business rights for this project and intends to actively drive its development.

This service comprehensively analyzes the intestinal microbiome of companion animals to assess the risk of eight major diseases in dogs—digestive, renal, circulatory, hepatic, metabolic, orthopedic, dermatological disorders, and obesity—covering a total of 14 specific conditions. Instead of disease diagnosis, it provides a customized report focused on health management.

With the expanding pet market and growing demand for precision healthcare, the number of households raising companion animals in Korea is increasing. At the same time, pet owners’ consumption patterns are rapidly shifting from price-oriented to value-oriented. In particular, there is a clear trend toward providing human-level healthcare for pets, as interest in their health, longevity, and quality of life continues to rise.

Lee Sangwook, CEO of DHX Company, stated, “Through this joint venture in companion animal healthcare, we will accelerate the discovery of new businesses and diversification within the ICT Distribution Division, and expand our existing microbiome technology capabilities into the pet healthcare market to secure future growth engines.”

This content was produced with the assistance of AI translation services.